China SXT Pharmaceuticals (SXTC) Debt to Equity (2019 - 2025)

China SXT Pharmaceuticals' Debt to Equity history runs 7 years deep, the most recent figure standing at $0.01 for Q1 2025.

• In Q1 2025, Debt to Equity fell 84.47% year-over-year to $0.01; the TTM figure through Mar 2025 stood at $0.01 (down 84.47% YoY), while the FY2025 annual figure was $0.01, down 84.47% from the prior year.
• Debt to Equity was $0.01 for Q1 2025 at China SXT Pharmaceuticals, down from $0.04 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.76 in Q1 2021 to a low of $0.0 in Q1 2022.
• Historically, Debt to Equity has averaged $0.17 across 5 years, with a median of $0.02 in 2023.
• The sharpest annual moves came in 2022 and 2023: Debt to Equity slumped 99.91% in 2022, then jumped 2638.9% in 2023.
• A 5-year view of Debt to Equity shows it stood at $0.76 in 2021, then plunged by 99.91% to $0.0 in 2022, then surged by 2638.9% to $0.02 in 2023, then jumped by 125.54% to $0.04 in 2024, then slumped by 84.47% to $0.01 in 2025.
• The last three Debt to Equity figures came in at $0.01 (Q1 2025), $0.04 (Q1 2024), and $0.02 (Q1 2023), per Business Quant data.